Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Cancer Response Using Axelopran in Patients With Advanced Cancers on Opioids (AxeCan)

NCT07354919 is registered in ClinicalTrials.gov with HealthPartners Institute as lead sponsor.

NCT NCT07354919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07354919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Cancer Response Using Axelopran in Patients With Advanced Cancers on Opioids (AxeCan)
Lead sponsor
HealthPartners Institute
Phase
Phase 2
Overall status
Recruiting
Start date
April 27, 2026
Completion date
November 1, 2028
Enrollment
34 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, lung cancer, pancreas cancer, prostate cancer